Table 2. FIRE 3 study, primary end points of (PFS and OS) efficacy results according to RAS mutation status.
| Variable | FOLFIRI + cetuximab (months) | FOLFIRI + bevacizumab (months) | P value |
|---|---|---|---|
| PFS | |||
| KRAS exon 2 (12+13) wild | 10.0 | 10.3 | 0.55 |
| Extended RAS wild-type [Excluding all non KRAS exon 2 (12+13) mutation]* | 10.4 | 10.2 | 0.54 |
| OS | |||
| KRAS exon 2 (12+13) wild | 28.7 | 25.0 | 0.017 |
| Extended RAS wild-type [Excluding all non KRAS exon 2 (12+13) mutation]* | 33.1 | 25.6 | 0.011 |
*exon 3 (codon 61), and exon 4 (codon 146), and NRAS exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146). Abbreviations: PFS, progression free survival; OS, overall survival.